AMGN Amgen Inc.

154.07
+1.05  (1%)
Previous Close 153.02
Open 152.65
Price To book 3.68
Market Cap 113.30B
Shares 735,399,000
Volume 3,581,999
Short Ratio 1.76
Av. Daily Volume 3,644,520

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved April 15, 2015.
Corlanor
Chronic Heart Failure
Phase 3 cardiovascular outcomes study data released March 17, 2017 - endpoints met but down on expectations.
Repatha
Cardiovascular disease
sBLA filing announced April 4, 2017. Standard 10-month review would render a PDUFA date on or about February 4, 2017. Awaiting confirmation.
XGEVA
Multiple Myeloma
Phase 3 commencement announced December 1, 2016.
Omecamtiv mecarbil GALACTIC-HF
Acute heart failure
Phase 3 trial initiated June 2015.
KYPROLIS (ARROW)
Multiple Myeloma
Phase 3 trial met PFS endpoint - March 2015. Announced February 28, 2017 that interim analysis met secondary endpoint of overall survival (OS).
KYPROLIS (ENDEAVOR)
Relapsed Multiple Myeloma
Phase 3 trial met primary endpoint September 2016. BLA filing announced May 18, 2017.
Erenumab
Migraine
PDUFA date under priority review August 14, 2017.
BLINCYTO
Ph+ R/R ALL
BLA filing due 2017.
ABP 980
Herceptin biosimilar
Phase 3 enrolling. Estimate data 1H 2018 using clinicaltrials.gov data.
ABP 798
RITUXAN biosimilar - non-Hodgkin lymphoma
Phase 3 enrolling.
ABP 710
REMICADE biosimilar - rheumatoid arthritis
Phase 2/3 ongoing.
CNP 520
Alzheimer’s Disease
Approved February 7, 2017.
Parsabiv
Secondary hyperparathyroidism (SHPT)
PDUFA date July 19, 2017. However, likely to be delayed due to safety data from ARCH trial released May 22, 2017.
EVENITY (Romosozumab)
Osteoporosis
BLA submission announced August 9, 2016. PDUFA date estimate June 9, 2017.
CHS-1701
Pegfilgrastim biosimilar